A. R. Marco

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab

A. Wollenberg, A. Blauvelt, A. Shabbir, 2022, Advances in Therapy.

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

J. Silverberg, C. Patruno, K. Abuabara, 2023, American Journal of Clinical Dermatology.

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

M. D. de Bruin‐Weller, T. Nakahara, A. Shabbir, 2022, American Journal of Clinical Dermatology.

Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

M. Boguniewicz, A. R. Marco, Shigemi Yoshihara, 2024, Advances in therapy.